Bristol Myers Squibb GC to Retire After 33 years With Drugmaker
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make decisions quickly and to be accountable for those decisions."
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week
A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The trades have taken place between February 18, 2025 and February 21, 2025. • JPMorgan Chase (NYSE:JPM) disclosed a series of transactions this week.
Bristol Myers Squibb Lights the Way to Treasury Innovation
For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with Celgene in one of the biggest acquisitions in pharmaceutical history, the company’s treasury team needed to regroup.
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid long-term pick despite short-term risks.
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.
Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 6,117.
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.
Research Analysts Issue Forecasts for BMY Q1 Earnings
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
FiercePharma4d
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Bristol Myers announces OS from Phase 3 CheckMate -816 study
Squibb announced the final analysis of overall survival, or OS, from the Phase 3 CheckMate -816 study, which evaluated ...
GlobalData on MSN6d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Hosted on MSN2d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Bristol Myers reports no new safety signals observed in five-year Sotyktu data
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...